Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Recovery-Story Buy: Emergent BioSolutions or Invitae?


Sometimes, a company hits a stumbling block -- or several of them. The stock plummets, and investors lose faith. But, in some cases, these down-on-their luck companies are able to turn things around. And if you spot signs of a bright future early enough, you can get in on the stock at a bargain price -- and reap the rewards later.

Two possibilities today are Emergent BioSolutions (NYSE: EBS) and Invitae (NYSE: NVTA). Their share prices have dropped 68% and 54%, respectively, over the past year. Both companies have catalysts ahead that could help lift the shares. But which is the better recovery-story buy? Let's find out.

Emergent BioSolutions specializes in products that address public-health threats. Among these are vaccines for smallpox and anthrax. The company also won contracts to produce coronavirus vaccines for Johnson Johnson and . Unfortunately, back in 2021, manufacturing errors led to a halt in production, and almost 400 million vaccine doses had to be destroyed, according to a Congressional investigation.

Continue reading


Source Fool.com

Astrazeneca ADR Stock

€72.00
0.700%
The Astrazeneca ADR stock is trending slightly upwards today, with an increase of €0.50 (0.700%) compared to yesterday's price.

Like: 0
EBS
Share

Comments